Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
New profilaxis
- Development stage
- Unknown
- Lead developer
- Maimonides Biomedical Research Institute of Córdoba
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
New profilaxis refers to a prophylactic drug regimen or protocol evaluated in clinical trials for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who receive induction therapy with thymoglobulin. The term appears to be used as a study arm or investigational approach rather than a specific, approved pharmaceutical product. In the referenced trial, "New profilaxis" is compared against standard prophylactic regimens, with the hypothesis that valganciclovir prophylaxis can be safely discontinued before three months if patients develop CMV-specific cellular immunity post-transplantation[1][2]. The mechanism of action would depend on the actual drug(s) used within this protocol; based on context, valganciclovir is likely involved as an antiviral agent inhibiting viral DNA synthesis.
- Brand names
- New profilaxis
- Other names
- New profilaxis
02
Targets
CMV DNA polymerase (Human cytomegalovirus DNA polymerase)
Beyond the preview
Go deeper on New profilaxis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New profilaxis.